首页> 外文OA文献 >A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

【2h】

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

机译：BIBW 2992（一项不可逆的表皮生长因子受体I（EGFR）和2（HER2）酪氨酸激酶双重抑制剂）的I期剂量递增研究在进展期为2周，2周为期的晚期实体瘤患者中进行

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Eskens Falm; Mom C. H.; Planting A. S. T.; Gietema J. A.; Amelsberg A.; Huisman H.; van Doorn L.; Burger H.; Stopfer P.; Verweij J.; de Vries Ege;
展开▼
作者单位

展开▼
年度 2008
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J] . F A L M Eskens, C H Mom, A S T Planting, British Journal of Cancer . 2008,第1期

机译：BIBW 2992（一项不可逆的表皮生长因子受体1（EGFR）和2（HER2）酪氨酸激酶双重抑制剂）的I期剂量递增研究在进展期为2周，2周为期的晚期实体瘤患者中进行
2. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J] . F A L M Eskens, C H Mom, A S T Planting, British Journal of Cancer . 2008,第1期

机译：BIBW 2992（一项不可逆的表皮生长因子受体1（EGFR）和2（HER2）酪氨酸激酶双重抑制剂）的I期剂量递增研究在进展期为2周，2周为期的晚期实体瘤患者中进行
3. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours [J] . Spicer J., Baird R., Suder A., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第2期

机译：实体瘤患者S-222611（EGFR和HER2的口服可逆酪氨酸激酶双重抑制剂）的1期剂量递增研究
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A phase I dose escalation study of BIBW 2992 an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on 2-week off schedule in patients with advanced solid tumours [O] . F A L M Eskens, C H Mom, A S T Planting, 2008

机译：BIBW 2992的I期剂量递增研究是表皮生长因子受体1（EGFR）和2（HER2）酪氨酸激酶的不可逆双重抑制剂在进展期2周2周的时间表中用于晚期实体瘤患者
7. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [O] . Eskens, F.A.L.M. (Ferry), Mom, C.H. (Constantijne), Planting, A.S.Th. (André), 2008

机译：BIBW 2992的I期剂量递增研究是表皮生长因子受体1（EGFR）和2（HER2）酪氨酸激酶的不可逆双重抑制剂，在进展期2周，2周的时间表中用于晚期实体瘤患者

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

著录项

引文网络

相似文献

相关主题

期刊订阅